retatrutide triple agonist Retatrutide, a agonist, delivered 30.3% weight loss at two years in Phase 3. The headlines state: → 70 lbs average loss on 12mg at 80 weeks (28.3% of body weight) → Retatrutide vs Mounjaro: triple agonist

Glucagon, first discovered in 1923 but only chemically characterized in the early 1970s, has now been established as a regulatory hormone capable of countering the effects of insulin

Multiple randomized trials (SEMAGLUTIDE ER vs

doi: 10.3389/fendo.2022.882998 Received 24 February 2022 Accepted 21 September 2022 Published 10 October 2022 Volume 13 - 2022 Edited by ke Sjholm, Gvle Hospital, Sweden Reviewed by Zhanna Belaya, Endocrinology Research Center, Russia

Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H

Consistency was key for generating robust data on weight loss and metabolic health, and subjects who missed multiple weekly administrations risked reducing the accuracy of the results